Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

BACKGROUND The characterization of the genes encoding melanoma-associated antigens MART-1 or gp100, recognized by T cells, has opened new possibilities for the development of immunization strategies for patients with metastatic melanoma. With the use of recombinant adenoviruses expressing either MART-1 or gp100 to immunize patients with metastatic melanoma, we evaluated the safety, immunologic, and potential therapeutic aspects of these immunizations. METHODS In phase I studies, 54 patients received escalating doses (between 10(7) and 10(11) plaque-forming units) of recombinant adenovirus encoding either MART-1 or gp100 melanoma antigen administered either alone or followed by the administration of interleukin 2 (IL-2). The immunologic impact of these immunizations on the development of cellular and antibody reactivity was assayed. RESULTS Recombinant adenoviruses expressing MART-1 or gp100 were safely administered. One of 16 patients with metastatic melanoma receiving the recombinant adenovirus MART-1 alone experienced a complete response. Other patients achieved objective responses, but they had received IL-2 along with an adenovirus, and their responses could be attributed to the cytokine. Immunologic assays showed no consistent immunization to the MART-1 or gp100 transgenes expressed by the recombinant adenoviruses. High levels of neutralizing antibody were found in the pretreatment sera of the patients. CONCLUSIONS High doses of recombinant adenoviruses could be safely administered to cancer patients. High levels of neutralizing antibody present in patients' sera prior to treatment may have impaired the ability of these viruses to immunize patients against melanoma antigens.

[1]  Joseph Zabner,et al.  Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis , 1993, Cell.

[2]  H. Ertl,et al.  Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1996, Gene therapy.

[3]  H. Ertl,et al.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.

[4]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[5]  S. Rosenberg,et al.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.

[6]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[7]  J. Renauld,et al.  Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes , 1995, Immunological reviews.

[8]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[9]  J. Cormier,et al.  Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.

[10]  S. Rosenberg,et al.  Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. , 1996, Journal of immunology.

[11]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[12]  J. Wilson,et al.  Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. , 1994, Circulation.

[13]  B. A. French,et al.  The Advent of Adenovirus Gene Therapy for Cardiovascular Disease , 1993, Circulation.

[14]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Zinkernagel,et al.  Induction of Protective Cytotoxic T Cell Responses in the Presence of High Titers of  Virus-neutralizing Antibodies: Implications for Passive and Active Immunization , 1998, The Journal of experimental medicine.

[16]  R. Gregory,et al.  Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway , 1997, Gene Therapy.

[17]  P. Chanda,et al.  Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. , 1993, AIDS research and human retroviruses.

[18]  F. Graham,et al.  Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. , 1991, Journal of acquired immune deficiency syndromes.

[19]  R. Johnson,et al.  Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. , 1996, Gene therapy.

[20]  F. H. Top.  Control of adenovirus acute respiratory disease in U.S. Army trainees. , 1975, The Yale journal of biology and medicine.

[21]  R. Crystal,et al.  Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. , 1997, Human gene therapy.

[22]  R. Ricciardi,et al.  Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. , 1997, Journal of immunology.

[23]  E. Nabel,et al.  Gene therapy for cardiovascular disease. , 1995, Circulation.

[24]  S. Rosenberg,et al.  Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.

[25]  S. Rosenberg.  Cancer vaccines based on the identification of genes encoding cancer regression antigens. , 1997, Immunology today.

[26]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[27]  J. Gall,et al.  Circumventing the immune response to adenovirus-mediated gene therapy. , 1996, Gene therapy.

[28]  M. Kay,et al.  Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Takeshita,et al.  Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[30]  J. Imler.  Adenovirus vectors as recombinant viral vaccines. , 1995, Vaccine.

[31]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[32]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[33]  S. Rosenberg,et al.  The development of new cancer therapies based on the molecular identification of cancer regression antigens. , 1995, The cancer journal from Scientific American.

[34]  A. Ribas,et al.  Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. , 1997, Cancer research.

[35]  M. Salgaller,et al.  Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[36]  M. Levine,et al.  Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. , 1992, Vaccine.

[37]  G. Contreras,et al.  Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines. , 1986, Canadian journal of public health = Revue canadienne de sante publique.

[38]  D. Dichek,et al.  Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. , 1997, The Journal of clinical investigation.

[39]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Welsh,et al.  Safety and efficacy of repetitive adenovirus–mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats , 1994, Nature Genetics.

[41]  J. Wilson,et al.  Gene therapy: adenovirus vectors. , 1993, Current opinion in genetics & development.

[42]  R. Crystal,et al.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis , 1994, Nature Genetics.

[43]  F. Marincola,et al.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.

[44]  B. Trapnell,et al.  Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. , 1994, Gene therapy.

[45]  M. Perricaudet,et al.  Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. , 1993, The Journal of clinical investigation.

[46]  M. Welsh,et al.  Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. , 1993, Human gene therapy.

[47]  S. Rosenberg.  Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. , 1996, Journal of the National Cancer Institute.